Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals.
COVID-19
SARS-CoV-2
elderly
neutralization
serology
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
02
05
2023
accepted:
19
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
SARS-CoV-2 infections have disproportionally burdened elderly populations with excessive mortality. While several contributing factors exists, questions remain about the quality and duration of humoral antibody-mediated responses resulting from infections in unvaccinated elderly individuals. Residual serum/plasma samples were collected from individuals undergoing routine SARS-CoV-2 polymerase chain reaction testing in a community laboratory in Canada. The samples were collected in 2020, before vaccines became available. IgG, IgA, and IgM antibodies against SARS-CoV-2 nucleocapsid, trimeric spike, and its receptor-binding domain were quantified via a high-throughput chemiluminescent enzyme-linked immunosorbent assay. Neutralization efficiency was also quantified through a surrogate high-throughput protein-based neutralization assay. This study analyzed SARS-CoV-2 antibody levels in a large cross-sectional cohort (N = 739), enriched for elderly individuals (median age, 82 years; 75% >65 years old), where 72% of samples tested positive for SARS-CoV-2 by polymerase chain reaction. The age group ≥90 years had higher levels of antibodies than that <65 years. Neutralization efficiency showed an age-dependent trend, where older persons had higher levels of neutralizing antibodies. Antibodies targeting the nucleocapsid had the fastest decline. IgG antibodies targeting the receptor-binding domain remained stable over time, potentially explaining the lack of neutralization decay observed in this cohort. Despite older individuals having the highest levels of antibodies postinfection, they are the cohort in which antibody decay was the fastest. Until a better understanding of correlates of protection is acquired, along with the protective role of nonneutralizing antibodies, booster vaccinations remain important in this demographic.
Sections du résumé
Background
UNASSIGNED
SARS-CoV-2 infections have disproportionally burdened elderly populations with excessive mortality. While several contributing factors exists, questions remain about the quality and duration of humoral antibody-mediated responses resulting from infections in unvaccinated elderly individuals.
Methods
UNASSIGNED
Residual serum/plasma samples were collected from individuals undergoing routine SARS-CoV-2 polymerase chain reaction testing in a community laboratory in Canada. The samples were collected in 2020, before vaccines became available. IgG, IgA, and IgM antibodies against SARS-CoV-2 nucleocapsid, trimeric spike, and its receptor-binding domain were quantified via a high-throughput chemiluminescent enzyme-linked immunosorbent assay. Neutralization efficiency was also quantified through a surrogate high-throughput protein-based neutralization assay.
Results
UNASSIGNED
This study analyzed SARS-CoV-2 antibody levels in a large cross-sectional cohort (N = 739), enriched for elderly individuals (median age, 82 years; 75% >65 years old), where 72% of samples tested positive for SARS-CoV-2 by polymerase chain reaction. The age group ≥90 years had higher levels of antibodies than that <65 years. Neutralization efficiency showed an age-dependent trend, where older persons had higher levels of neutralizing antibodies. Antibodies targeting the nucleocapsid had the fastest decline. IgG antibodies targeting the receptor-binding domain remained stable over time, potentially explaining the lack of neutralization decay observed in this cohort.
Conclusions
UNASSIGNED
Despite older individuals having the highest levels of antibodies postinfection, they are the cohort in which antibody decay was the fastest. Until a better understanding of correlates of protection is acquired, along with the protective role of nonneutralizing antibodies, booster vaccinations remain important in this demographic.
Identifiants
pubmed: 37547857
doi: 10.1093/ofid/ofad384
pii: ofad384
pmc: PMC10404006
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad384Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors declare no conflict of interest.
Références
Nat Commun. 2021 Apr 1;12(1):2037
pubmed: 33795692
Nat Aging. 2022 Jun;2(6):536-547
pubmed: 37118449
Diagn Microbiol Infect Dis. 2022 May;103(1):115659
pubmed: 35278794
J Clin Invest. 2011 Dec;121(12):4921-30
pubmed: 22105170
Nat Aging. 2021 Sep;1(9):769-782
pubmed: 34746804
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Cell Mol Immunol. 2021 Oct;18(10):2293-2306
pubmed: 34497376
Blood. 2000 May 1;95(9):2860-8
pubmed: 10779432
Biomed Res Int. 2020 Nov 4;2020:8870249
pubmed: 33204723
Front Public Health. 2021 Aug 06;9:584182
pubmed: 34422736
Nat Commun. 2022 Jul 1;13(1):3716
pubmed: 35778399
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Am J Epidemiol. 1996 May 15;143(10):1042-9
pubmed: 8629611
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
J Infect Dis. 2022 Sep 21;226(6):983-994
pubmed: 35543278
J Immunol. 2017 Aug 1;199(3):1060-1068
pubmed: 28646038
Transpl Int. 2009 Nov;22(11):1041-50
pubmed: 19624493
Pediatr Infect Dis J. 2022 Aug 1;41(8):e318-e320
pubmed: 35544731
J Immunol. 2014 Mar 15;192(6):2689-98
pubmed: 24510963
J Immunol. 2013 Feb 15;190(4):1746-57
pubmed: 23319733
J Infect Dis. 2021 Sep 1;224(5):764-770
pubmed: 34086960
Clin Transl Immunology. 2022 Mar 23;11(3):e1380
pubmed: 35356067
Influenza Other Respir Viruses. 2012 Jan;6(1):52-62
pubmed: 21668661
Pathogens. 2021 Jun 20;10(6):
pubmed: 34203060
Clin Infect Dis. 2022 Apr 9;74(7):1220-1229
pubmed: 34218284
Aging Cell. 2020 Oct;19(10):e13230
pubmed: 33006233
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
JAMA Netw Open. 2020 Jul 1;3(7):e2015957
pubmed: 32697325
Front Immunol. 2018 Jan 10;8:1960
pubmed: 29375577
GMS Hyg Infect Control. 2021 Mar 15;16:Doc11
pubmed: 33796439
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Leukoc Biol. 2015 Dec;98(6):937-43
pubmed: 26188078
Commun Med (Lond). 2022 May 19;2:53
pubmed: 35603297
Signal Transduct Target Ther. 2020 Sep 2;5(1):180
pubmed: 32879307
J Clin Immunol. 2000 Jul;20(4):240-9
pubmed: 10939711
EBioMedicine. 2021 Dec;74:103700
pubmed: 34861490
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Clin Infect Dis. 2015 Dec 15;61(12):1835-8
pubmed: 26265498
Clin Infect Dis. 2020 Dec 17;71(10):2688-2694
pubmed: 32497196
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Pathol. 2007 Jan;211(2):144-56
pubmed: 17200946
Clin Infect Dis. 2003 Apr 1;36(7):870-6
pubmed: 12652388
Microbiol Spectr. 2021 Oct 31;9(2):e0090421
pubmed: 34668738
J Am Geriatr Soc. 2014 Jul;62(7):1310-6
pubmed: 24852422
J Clin Virol. 2013 Sep;58(1):262-4
pubmed: 23895931
Aging Cell. 2014 Aug;13(4):690-8
pubmed: 24779584
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330709